Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single and Multiple Ascending Dose Study of JNJ-40411813 in Healthy Japanese Males
jRCT2071200090Phase 1Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in epilepsy comparing JNJ-40411813 with Placebo (2 arms). Primary endpoints: Number of Participants with Adverse Events (Parts 1 and 2), Number of Participants with Adverse Events (Part 3) and 2 more. Started Feb 2021; status: active, not recruiting.
02
Drugs
adx-71149
03
Conditions
epilepsy
Beyond the preview
Go deeper on jRCT2071200090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071200090.